Diligence memo · auto-generated · as of July 3, 2026
Cullinan Mica Corp.
Cullinan Mica Corp. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cullinan Mica Corp. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cullinan Mica Corp. has raised $27M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $17M on 2020-05-28.
Most recent recorded round closed around 2022-03-10.
Valuation (modeled)modeled
Provath models Cullinan Mica Corp. at approximately $174M (range $21M–$486M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.34× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (134% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.